Literature DB >> 29582270

Indications for salvage surgery during treatment for intracranial germ cell tumors.

Masayuki Kanamori1, Toshihiro Kumabe2, Mika Watanabe3, Masashi Chonan4, Ryuta Saito4, Yoji Yamashita5, Yoshikazu Ogawa6, Yukihiko Sonoda7, Teiji Tominaga4.   

Abstract

This study retrospectively reviewed our single institute experience to clarify the optimal indication and timing of salvage surgery. Retrospective analysis of 159 consecutive cases with germ cell tumors identified 20 cases with salvage surgery. These cases were classified based on the radiological response to neoadjuvant treatment before salvage surgery into increase (growing group, five cases), no change (stable group, seven cases), and decrease (shrinkage group, eight cases) in tumor size. Changes in tumor markers, histological findings, and the pattern of failure after salvage surgery were reviewed. Growing teratoma syndrome (GTS) is defined as enlargement of tumor consisting of mature teratoma after chemotherapy with normalization of tumor markers. In growing group, two cases presented GTS, whereas other three cases did not fulfill the criteria for GTS. All cases in stable and shrinkage group had elevated levels of tumor markers at presentation and decreased levels after neoadjuvant treatment. Histologically, sparse components of mature teratoma with extensive fibrosis were found in cases with GTS and seven of eight cases in shrinkage group, whereas mature teratoma without fibrosis was found in six of seven cases in stable group. Six cases recurred after salvage surgery. We identified three factors as risks for recurrence after salvage surgery, as follows: (1) growing lesion which did not fulfill the criteria for GTS, (2) non-normalized level of tumor marker before salvage surgery, and (3) residual germinoma component. In conclusion, salvage surgery is recommended for patients with GTS, or with normalized tumor markers in stable or shrinkage group.

Entities:  

Keywords:  Histological findings; Intracranial germ cell tumors; Salvage surgery

Mesh:

Substances:

Year:  2018        PMID: 29582270     DOI: 10.1007/s11060-018-2827-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  13 in total

1.  Management of malignant pineal germ cell tumors with residual mature teratoma.

Authors:  J A Friedman; J J Lynch; J C Buckner; B W Scheithauer; C Raffel
Journal:  Neurosurgery       Date:  2001-03       Impact factor: 4.654

2.  Intracranial growing teratoma syndrome: clinical characteristics and treatment strategy.

Authors:  Chae-Yong Kim; Jung-Won Choi; Ji Yeon Lee; Seung-Ki Kim; Kyu-Chang Wang; Sung-Hye Park; Gheeyoung Choe; Hyo Seop Ahn; Il-Han Kim; Byung-Kyu Cho
Journal:  J Neurooncol       Date:  2010-06-09       Impact factor: 4.130

3.  Delayed surgical resection of central nervous system germ cell tumors.

Authors:  Howard L Weiner; Roger A Lichtenbaum; Jeffrey H Wisoff; Robert B Snow; Mark M Souweidane; Jeffrey N Bruce; Jonathan L Finlay
Journal:  Neurosurgery       Date:  2002-04       Impact factor: 4.654

4.  Metachronous neurohypophysical immature teratoma occurring 10 years after total resection of pineal mature teratoma.

Authors:  T Hirano; T Kumabe; K Murakami; M Watanabe; R Shirane; T Yoshimoto
Journal:  Childs Nerv Syst       Date:  2001-04       Impact factor: 1.475

5.  Second-look surgery for intracranial germ cell tumors.

Authors:  Hideki Ogiwara; Chikako Kiyotani; Keita Terashima; Nobuhito Morota
Journal:  Neurosurgery       Date:  2015-06       Impact factor: 4.654

6.  [Recurrence of intracranial germinoma initially treated with chemotherapy only].

Authors:  Toshihiro Kumabe; Yasuko Kusaka; Hidefumi Jokura; Hidetoshi Ikeda; Reizo Shirane; Takashi Yoshimoto
Journal:  No Shinkei Geka       Date:  2002-09

7.  Optimal treatment strategy for intracranial germ cell tumors: a single institution analysis.

Authors:  Masayuki Kanamori; Toshihiro Kumabe; Ryuta Saito; Yoji Yamashita; Yukihiko Sonoda; Hisanori Ariga; Yoshihiro Takai; Teiji Tominaga
Journal:  J Neurosurg Pediatr       Date:  2009-12       Impact factor: 2.375

8.  Successful treatment of intracranial nongerminomatous malignant germ cell tumors by administering neoadjuvant chemotherapy and radiotherapy before excision of residual tumors.

Authors:  Masato Kochi; Youichi Itoyama; Shoji Shiraishi; Isao Kitamura; Toru Marubayashi; Yukitaka Ushio
Journal:  J Neurosurg       Date:  2003-07       Impact factor: 5.115

9.  The growing teratoma syndrome.

Authors:  C J Logothetis; M L Samuels; A Trindade; D E Johnson
Journal:  Cancer       Date:  1982-10-15       Impact factor: 6.860

10.  Is histological diagnosis necessary to start treatment for germ cell tumours in the pineal region?

Authors:  Masayuki Kanamori; Toshihiro Kumabe; Teiji Tominaga
Journal:  J Clin Neurosci       Date:  2008-07-09       Impact factor: 1.961

View more
  2 in total

Review 1.  Intracranial growing teratoma syndrome observed at 44 months after initial treatment; a case presentation and literature review.

Authors:  Shunsuke Yanagisawa; Koichiro Okamoto; Shoji Yamaguchi; Yuta Tamai; Makiko Fujitani; Masato Inoue; Tetsuo Hara
Journal:  Childs Nerv Syst       Date:  2019-12-18       Impact factor: 1.475

2.  So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?

Authors:  Masayuki Kanamori; Hirokazu Takami; Shigeru Yamaguchi; Takashi Sasayama; Koji Yoshimoto; Teiji Tominaga; Akihiro Inoue; Naokado Ikeda; Atsushi Kambe; Toshihiro Kumabe; Masahide Matsuda; Shota Tanaka; Manabu Natsumeda; Ken-Ichiro Matsuda; Masahiro Nonaka; Jun Kurihara; Masayoshi Yamaoka; Naoki Kagawa; Naoki Shinojima; Tetsuya Negoto; Yukiko Nakahara; Yoshiki Arakawa; Seiji Hatazaki; Hiroaki Shimizu; Atsuo Yoshino; Hiroshi Abe; Jiro Akimoto; Yu Kawanishi; Tomonari Suzuki; Atsushi Natsume; Motoo Nagane; Yukinori Akiyama; Dai Keino; Tadateru Fukami; Takahiro Tomita; Kohei Kanaya; Tsutomu Tokuyama; Shuichi Izumoto; Mitsutoshi Nakada; Daisuke Kuga; Shohei Yamamoto; Ryogo Anei; Takeo Uzuka; Junya Fukai; Noriyuki Kijima; Keita Terashima; Koichi Ichimura; Ryo Nishikawa
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.